Your cart is empty
Start Shopping
$99.00
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
| Molecular Formula | C32H49N9O5 |
| CAS Number | 736992-21-5 |
| Molar Mass | 639.802 g/mol |
| Amino Acid Sequence | D-Arg-Dmt-Lys-Phe-NH2 |
| PubChem CID | 11764719 |
| Primary Research Area |
Renal aging and mitochondrial dysfunction. Mitochondrial bioenergetics and inflammation. Neurodegenerative disease and mitochondrial protection. Cardiac metabolism and mitochondrial cardiomyopathy. Diabetic nephropathy and oxidative stress. Chronic kidney disease Ototoxicity prevention and mitochondrial drug delivery. |
| Research Summary | Description |
|---|---|
| The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age |
Summary:This study demonstrated that SS-31 administration in aged mice restored mitochondrial function within renal glomeruli, reduced oxidative stress, and improved podocyte integrity. Treatment resulted in preserved glomerular structure and overall kidney function. Implication: These findings suggest that SS-31 may serve as a therapeutic agent for age-associated renal decline by stabilizing mitochondrial function and mitigating oxidative injury in kidney tissues. Citation: Sweetwyne, M. T., Pippin, J. W., Eng, D. G., Hudkins, K. L., Chiao, Y. A., Campbell, M. D., ... & Shankland, S. J. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney international, 91(5), 1126-1145. |
| Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis |
Summary:Researchers synthesized new SS-31 derivatives with improved efficacy. These analogs enhanced mitochondrial ATP production and displayed stronger anti-inflammatory properties compared to the parent peptide. Implication: This study highlights the potential of optimizing SS-31’s structure to develop more potent mitochondria-targeted therapeutics for metabolic and inflammatory diseases. Citations: Li, M., Kong, D., Meng, L., Wang, Z., Bai, Z., & Wu, G. (2024). Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. RSC advances, 14(41), 29789-29799. |
| Therapeutic peptide SS-31 modulates membrane binding and aggregation of α-synuclein and restores impaired mitochondrial function |
Summary:SS-31 was shown to interfere with α-synuclein membrane binding and aggregation, processes linked to mitochondrial dysfunction in neurodegenerative diseases. The peptide restored mitochondrial integrity and energy metabolism in affected cells. Implication: SS-31 demonstrates neuroprotective potential, offering a therapeutic avenue for conditions such as Parkinson’s disease by preventing protein aggregation and preserving mitochondrial health. Citation: Stefaniak, E., Cui, B., Sun, K., Yan, X., Teng, X., & Ying, L. (2024). Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. bioRxiv, 2024-07. |
| Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice |
Summary:In a tafazzin-deficient mouse model, SS-31 improved cardiac mitochondrial structure, enhanced ATP production, and reduced oxidative damage, leading to better cardiac performance. Implication: SS-31 may represent a promising treatment for mitochondrial cardiomyopathies, such as Barth syndrome, by restoring mitochondrial bioenergetics and cardiac function. Citations: Russo, S., De Rasmo, D., Signorile, A., Corcelli, A., & Lobasso, S. (2022). Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Scientific Reports, 12(1), 19847. |
| Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy |
Summary: SS-31 treatment in diabetic mice reduced renal oxidative stress, inflammation, and fibrosis while improving mitochondrial respiration and kidney morphology. Implication: These results indicate that SS-31 can be a potential therapeutic candidate for diabetic nephropathy through its antioxidant and mitochondrial-protective mechanisms. Citations:Hou, Y., Li, S., Wu, M., Wei, J., Ren, Y., Du, C., ... & Shi, Y. (2016). Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. American Journal of Physiology-Renal Physiology, 310(6), F547-F559. |
| SS-31, a mitochondria-targeting peptide, ameliorates kidney disease |
Summary:This study confirmed SS-31’s renoprotective effects by demonstrating decreased mitochondrial damage, reduced inflammatory responses, and improved renal function in kidney disease models. Implication: SS-31’s mitochondria-targeting mechanism offers a promising strategy for treating chronic kidney disease by maintaining mitochondrial stability and cellular homeostasis. Citations: Zhu, Y., Luo, M., Bai, X., Li, J., Nie, P., Li, B., & Luo, P. (2022). SS‐31, a mitochondria‐targeting peptide, ameliorates kidney disease. Oxidative Medicine and Cellular Longevity, 2022(1), 1295509. |
| SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides |
Summary:The study showed that SS-31 can facilitate targeted drug delivery to mitochondria in cochlear hair cells, reducing aminoglycoside-induced oxidative damage and preventing cell death. Implication: This research supports SS-31 as a novel platform for mitochondrial drug delivery and a potential therapeutic tool for preventing ototoxicity and hearing loss associated with antibiotic use. Citation: Kuang, X., Zhou, S., Guo, W., Wang, Z., Sun, Y., & Liu, H. (2017). SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides. Drug Delivery, 24(1), 1750-1761. |
Summary:This study demonstrated that SS-31 administration in aged mice restored mitochondrial function within renal glomeruli, reduced oxidative stress, and improved podocyte integrity. Treatment resulted in preserved glomerular structure and overall kidney function.
Implication: These findings suggest that SS-31 may serve as a therapeutic agent for age-associated renal decline by stabilizing mitochondrial function and mitigating oxidative injury in kidney tissues.
Citation: Sweetwyne, M. T., Pippin, J. W., Eng, D. G., Hudkins, K. L., Chiao, Y. A., Campbell, M. D., ... & Shankland, S. J. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney international, 91(5), 1126-1145.
Summary:Researchers synthesized new SS-31 derivatives with improved efficacy. These analogs enhanced mitochondrial ATP production and displayed stronger anti-inflammatory properties compared to the parent peptide.
Implication: This study highlights the potential of optimizing SS-31’s structure to develop more potent mitochondria-targeted therapeutics for metabolic and inflammatory diseases.
Citations: Li, M., Kong, D., Meng, L., Wang, Z., Bai, Z., & Wu, G. (2024). Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH 2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. RSC advances, 14(41), 29789-29799.
Summary:SS-31 was shown to interfere with α-synuclein membrane binding and aggregation, processes linked to mitochondrial dysfunction in neurodegenerative diseases. The peptide restored mitochondrial integrity and energy metabolism in affected cells.
Implication: SS-31 demonstrates neuroprotective potential, offering a therapeutic avenue for conditions such as Parkinson’s disease by preventing protein aggregation and preserving mitochondrial health.
Citation: Stefaniak, E., Cui, B., Sun, K., Yan, X., Teng, X., & Ying, L. (2024). Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. bioRxiv, 2024-07.
Summary:In a tafazzin-deficient mouse model, SS-31 improved cardiac mitochondrial structure, enhanced ATP production, and reduced oxidative damage, leading to better cardiac performance.
Implication: SS-31 may represent a promising treatment for mitochondrial cardiomyopathies, such as Barth syndrome, by restoring mitochondrial bioenergetics and cardiac function.
Citations: Russo, S., De Rasmo, D., Signorile, A., Corcelli, A., & Lobasso, S. (2022). Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Scientific Reports, 12(1), 19847.
Summary: SS-31 treatment in diabetic mice reduced renal oxidative stress, inflammation, and fibrosis while improving mitochondrial respiration and kidney morphology.
Implication: These results indicate that SS-31 can be a potential therapeutic candidate for diabetic nephropathy through its antioxidant and mitochondrial-protective mechanisms.
Citations:Hou, Y., Li, S., Wu, M., Wei, J., Ren, Y., Du, C., ... & Shi, Y. (2016). Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. American Journal of Physiology-Renal Physiology, 310(6), F547-F559.
Summary:This study confirmed SS-31’s renoprotective effects by demonstrating decreased mitochondrial damage, reduced inflammatory responses, and improved renal function in kidney disease models.
Implication: SS-31’s mitochondria-targeting mechanism offers a promising strategy for treating chronic kidney disease by maintaining mitochondrial stability and cellular homeostasis.
Citations: Zhu, Y., Luo, M., Bai, X., Li, J., Nie, P., Li, B., & Luo, P. (2022). SS‐31, a mitochondria‐targeting peptide, ameliorates kidney disease. Oxidative Medicine and Cellular Longevity, 2022(1), 1295509.
Summary:The study showed that SS-31 can facilitate targeted drug delivery to mitochondria in cochlear hair cells, reducing aminoglycoside-induced oxidative damage and preventing cell death.
Implication: This research supports SS-31 as a novel platform for mitochondrial drug delivery and a potential therapeutic tool for preventing ototoxicity and hearing loss associated with antibiotic use.
Citation: Kuang, X., Zhou, S., Guo, W., Wang, Z., Sun, Y., & Liu, H. (2017). SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides. Drug Delivery, 24(1), 1750-1761.
Your cart is empty
Start Shopping